These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 26052395)

  • 41. Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy.
    Lin CL; Wu SY; Lai MW; Hsu CW; Chen WM; Jao AT; Chien CH; Hu CC; Chien RN; Yeh CT
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent developments in antivirals against hepatitis B virus.
    Wang YJ; Yang L; Zuo JP
    Virus Res; 2016 Feb; 213():205-213. PubMed ID: 26732483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Dakin H; Fidler C; Harper C
    Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
    Arnold E; Yuan Y; Iloeje U; Cook G
    Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
    Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
    J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy.
    Wu L; Yang Z; Zheng M
    J Viral Hepat; 2024 May; 31(5):255-265. PubMed ID: 38332479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues.
    Buti M; Roade L; Riveiro-Barciela M; Esteban R
    Liver Int; 2020 Feb; 40 Suppl 1():15-21. PubMed ID: 32077604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
    Orita N; Kawaguchi K; Honda M; Shimode T; Hayakawa N; Terashima T; Komura T; Nishikawa M; Horii R; Nio K; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S; Kagaya T; Yamashita T
    Biochem Biophys Res Commun; 2023 Sep; 674():133-139. PubMed ID: 37419034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.
    Kim SK; Fujii T; Kim SR; Nakai A; Lim YS; Hagiwara S; Kudo M
    Liver Cancer; 2022 Dec; 11(6):497-510. PubMed ID: 36589728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors.
    Li ZQ; Hu CL; Yu P; Gu XY; Zhang JJ; Li H; Zhang HY; Lv J; Liu YM; Zeng QL; Yan JY; Yu ZJ; Zhang Y
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):311-318. PubMed ID: 28237828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
    Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
    J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis.
    Honda K; Seike M; Murakami K
    World J Hepatol; 2015 Oct; 7(22):2404-10. PubMed ID: 26464756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
    Öksüz Z; Serin MS; Serin A; Sezgin O; Gonca S
    Mikrobiyol Bul; 2019 Apr; 53(2):156-169. PubMed ID: 31130120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.